Asceneuron Receives USD 2.2 Million Award from the Alzheimer’s Drug Discovery Foundation

Award will fund first in human clinical trials of next generation O-GlcNAcase inhibitor, ASN51, to start Q2 2021

Asceneuron SA, an emerging leader in the development of treatments for neurodegenerative diseases, announced today the receipt of a USD 2.2 million award from the Alzheimer’s Drug Discovery Foundation (ADDF) for a first in human Phase I study of the Company’s next generation O-GlcNAcase inhibitor, ASN51. The trial is due to recruit healthy volunteers and Alzheimer’s disease patients at sites in Europe and Australia, to start in Q2 2021, with first interim data due in Q3 2021.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...